Another key point to be addressed in future clinical trials is the establishment of the most proper doses of novel incretin analogs required to achieve the desired clinical outcomes in different subgroups of patients with autoimmune diabetes (e.g., patients with new-onset T1D, patients with long-standing T1D, patients with double diabetes and overweight/obesity, patients with LADA). This evidence concerns the gene GCG and type 1 diabetes mellitus.